Alzheimer's disease

New England Journal of Medicine

Volumn 351, Issue 1, 2004, Pages 56-67+110

  Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DICLOFENAC; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; HALOPERIDOL; HUPERZINE A; MEDROXYPROGESTERONE; MEMANTINE; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; PREDNISONE; RISPERIDONE; RIVASTIGMINE; ROFECOXIB; SELEGILINE; TACRINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE; AMINO ACID RECEPTOR BLOCKING AGENT; AMYLOID BETA PROTEIN; PSYCHOTROPIC AGENT;

ALZHEIMER DISEASE; CLINICAL RESEARCH; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC IMAGING; DIARRHEA; DOSE RESPONSE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; LIVER TOXICITY; MUSCLE CRAMP; NAUSEA; NERVE DEGENERATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; UNITED STATES; UNPLEASANT DREAM; VOMITING; WEIGHT REDUCTION; BIOSYNTHESIS; BRAIN; CAREGIVER; CELL DEATH; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; SCINTISCANNING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIOXIDANTS; BRAIN; CAREGIVERS; CELL DEATH; CHOLINESTERASE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; PSYCHOTROPIC DRUGS;

EID: 3042857903     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra040223     Document Type: Review

References (90)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 Census. Arch Neurol 2003;60:1119-22.
2. Jorm AF. Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias. Eur Arch Psychiatry Clin Neurosci 1991;240:218-22.
3. Wimo A, Winblad B. Health economical aspects of Alzheimer disease and its treatment. Psychogeriatrics 2001;1:189-93.
4. Diagnostic and statistical manual of mental disorders, 4th ed. DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
5. Kawas CH. Early Alzheimer's disease. N Engl J Med 2003;349:1056-63.
6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
7. Chui H, Lee A-E. Clinical criteria for dementia subtypes. In: Qizilbash N, Schneider L, Brodaty H, et al., eds. Evidence-based dementia practice. Oxford, England: Blackwell Science, 2002:106-19.
8. Greene JD, Baddeley AD, Hodges JR. Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Neuropsychologia 1996;34:537-51.
9. Pillon B, Deweer B, Agid Y, Dubois B. Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol 1993;50:374-9.
10. Price BH, Gurvit H, Weintraub S, Geula C, Leimkuhler E, Mesulam M. Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer's disease. Arch Neurol 1993;50:931-7.
11. Esteban-Santillan C, Praditsuwan R, Ueda H, Geldmacher DS. Clock drawing test in very mild Alzheimer's disease. J Am Geriatr Soc 1998;46:1266-9.
12. Kirk A, Kertesz A. On drawing impairment in Alzheimer's disease. Arch Neurol 1991;48:73-7.
13. Galasko D, Bennett DA, Sano K, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:S33-S39.
14. Mega MS, Cummings JL, Fiorello T, Gombein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-5.
15. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53.
16. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120-7.
17. Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med 1995;122:422-9.
18. Ross GW, Abbott RD, Petrovitch H, et al. Frequency and characteristics of silent dementia among elderly Japanese-American men: the Honolulu-Asia Aging Study. JAMA 1997;277:800-5.
19. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6. [Erratum, Science 2002;297:2209.]
20. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6. [Erratum, Science 2002;297:2209.]
21. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 2002;23:655-64.
22. Carter DB, Dunn E, McKinley DD, et al. Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain. Ann Neurol 2001;50:468-75.
23. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
24. Mesulam M-M. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 1999;24:521-9.
25. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547-54.
26. Pappas BA, Bayley PJ, Bui BK, Hansen LA, Thal LJ. Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patients. Neurobiol Aging 2000;21:11-7.
27. Palmer AM, Stratmann GC, Procter AW, Bowen DM. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol 1988;23:616-20.
28. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-9.
29. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta 42 immunization. Neurology 2003;61:46-54.
30. Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov 2002;1:859-66.
31. Seimers ER, Quinn JL, Kaye J, et al. Effect of LY450139, a functional g-secretase inhibitor on plasma and cerebrospinal fluid concentrations of Ab and cognitive functioning in patients with mild to moderate Alzheimer's disease. Am Acad Neurol 2004;101:Suppl:S17. abstract.
32. Petanceska SS, DeRosa S, Olm V, et al. Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci 2002;19:155-61.
33. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60:1685-91.
34. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998;50:164-8.
35. Windisch M, Hutter-Paier B, Rockenstein E, Hashimoto M, Mallory M, Masliah E. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides. J Mol Neurosci 2002;19:63-9.
36. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-22.
37. Klatte ET, Scharre DW, Nagaraja HN, Davis RA, Beverdorf DQ. Combination therapy of donepezil and vitamin E in Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17:113-6.
38. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002;287:3223-9.
39. Esposito E, Rotilio D, Di Matteo V, Di Giulio C, Cacchio M, Algeri S. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Aging 2002;23:719-35.
40. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004;61:82-8.
41. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 1999;38:735-67.
42. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
43. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil; a randomized controlled trial. JAMA 2004;291:317-24.
44. Finch CE, Longo V, Miyao A, et al. Inflammation in Alzheimer's disease. In: Chesselet M-F, ed. Molecular mechanisms of neurodegenerative diseases. Totowa, N.J.: Humana Press, 2001:87-110.
45. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 2000;54:588-93.
46. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201.
47. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA 2003;289:2819-26.
48. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54:295-301.
49. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. JAMA 2000;283:1007-15. [Erratum, JAMA 2000;284:2597.]
50. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. JAMA 2000;283:1007-15. [Erratum, JAMA 2000;284:2597.]
51. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-62.
52. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology 2001;56:1154-66.
53. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer's disease and related disoiders: consensus statement of the American Association of Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-71.
54. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
55. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131-45.
56. Leber P. Guidelines for the clinical evaluation of antidementia drugs. Rockville, Md.: Food and Drug Administration, 1990.
57. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
58. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997;11:Suppl:S22-S32.
59. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-45.
60. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
61. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-8.
62. Doraiswamy PM, Kaiser L, Bieber F, Garman RL. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord 2001;15:174-83.
63. Tariot PN, Cummings J, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-9.
64. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95.
65. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000;10:195-203.
66. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-33.
67. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998;55:1409-15.
68. Ott BR, Owens NJ. Complementary and alternative medicines for Alzheimer's discase. J Geriatr Psychiatry Neurol 1998;11:163-73.
69. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001;9:361-81.
70. Cohen-Mansfield J, Werner P. Management of verbally disruptive behaviors in nursing home residents. J Gerontol A Biol Sci Med Sci 1997;52:M369-M377.
71. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107-15.
72. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-55.
73. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000;57:968-76.
74. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-43.
75. Devanand D, Marder K, Michaels K, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998;155:1512-20.
76. Sultzer D, Gray K, Gunay I, Berisford MA, Mahler ME. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997;5:60-9.
77. Tariot PN, Erb R, Podgorski C, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998;155:54-61.
78. Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001;9:58-66.
79. Porsteinsson AP, Tariot PN, Erb R, Gaile S. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry 1997;5:344-51.
80. Lyketsos C, Sheppard J-M, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 2000;157:1686-9.
81. Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998;13:100-8.
82. Taragano F, Lyketsos C, Mangone CA, Allegri RF, Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997;38:246-52.
83. Chandra V, Bharucha NE, Schoenberg BS. Conditions associated with Alzheimer's disease at death: case-control study. Neurology 1986;36:209-11.
84. Magenheim MJ. Preventive health maintenance. In: Duthie EH Jr, Katz PR, eds. Practice of geriatrics. 3rd ed. Philadelphia: W.B. Saunders, 1998:115-29.
85. Alzheimer's Association home page. (Accessed June 4, 2004, at: http://www.alz.org.)
86. Schulz R, O'Brien AT, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist 1995;35:771-91.
87. Mittelman MS, Ferris SH, Shulman E, Steinberg G, Levin B. A family intervention to delay nursing home placement of patients with Alzheimer disease: a randomized controlled trial. JAMA 1996;276:1725-31.
88. Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc 2003;51:657-64.
89. The Leeza Gibbons Memory Foundation home page. (Accessed June 4, 2004, at http://memoryfoundation.org.)
90. Alzheimer's Foundation of America home page. (Accessed June 4, 2004, at http://www.alzfdn.org.)